{"id":63924,"date":"2026-04-24T21:21:44","date_gmt":"2026-04-24T13:21:44","guid":{"rendered":"https:\/\/flcube.com\/?p=63924"},"modified":"2026-04-24T21:21:45","modified_gmt":"2026-04-24T13:21:45","slug":"huadong-medicine-secures-nmpa-approval-for-ellanse-m-pcl-microsphere-filler-for-temple-hollowing-correction","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63924","title":{"rendered":"Huadong Medicine Secures NMPA Approval for Ellans\u00e9 M PCL Microsphere Filler for Temple Hollowing Correction"},"content":{"rendered":"\n<p><strong>Huadong Medicine Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE: 000963<\/a>) announced it has received marketing approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>Ellans\u00e9 M<\/strong>, an injectable polycaprolactone (PCL) microsphere facial filler. The Class III medical device is specifically indicated for improving mild-to-moderate temple hollowing in adults when injected into the supraperiosteal layer, representing a significant advancement in regenerative aesthetic treatments.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Huadong Medicine Co., Ltd. (SHE: 000963)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Ellans\u00e9 M<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Class III medical device<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Approval Status<\/strong><\/td><td>Marketing approval granted<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Mild-to-moderate temple hollowing in adults<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Supraperiosteal injection in temple area<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Medical institutions only<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-composition-amp-mechanism-of-action\">Product Composition &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-dual-phase-technology-platform\">Dual-Phase Technology Platform<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immediate Effect<\/strong>: Carboxymethyl cellulose (CMC)-based gel carrier provides rapid filling and immediate contouring<\/li>\n\n\n\n<li><strong>Long-Term Regeneration<\/strong>: Polycaprolactone (PCL) microspheres stimulate sustained collagen neogenesis<\/li>\n\n\n\n<li><strong>Collagen Quality<\/strong>: Durable activation of orderly autologous collagen structure regeneration, particularly <strong>type I collagen<\/strong><\/li>\n\n\n\n<li><strong>Structural Support<\/strong>: Superior deep tissue support through natural collagen matrix formation<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-differentiation\">Clinical Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Anatomy<\/strong>: Specifically designed for temple area restoration<\/li>\n\n\n\n<li><strong>Injection Precision<\/strong>: Supraperiosteal layer delivery optimizes structural support<\/li>\n\n\n\n<li><strong>Regenerative Approach<\/strong>: Addresses underlying volume loss rather than temporary masking<\/li>\n\n\n\n<li><strong>Durability Profile<\/strong>: Extended results through natural collagen production versus temporary fillers<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-position-amp-strategic-impact\">Market Position &amp; Strategic Impact<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-aesthetic-market-dynamics\">Aesthetic Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Temple Hollowing<\/strong>: Increasingly recognized as key aging indicator in Asian aesthetics<\/li>\n\n\n\n<li><strong>Regenerative Trend<\/strong>: Shift toward collagen-stimulating products over traditional hyaluronic acid fillers<\/li>\n\n\n\n<li><strong>Premium Positioning<\/strong>: Ellans\u00e9 M targets high-end aesthetic segment seeking long-lasting, natural results<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Leadership<\/strong>: PCL microsphere technology represents advanced regenerative approach<\/li>\n\n\n\n<li><strong>Regulatory Advantage<\/strong>: NMPA approval provides first-mover advantage in temple-specific indication<\/li>\n\n\n\n<li><strong>Medical Channel Focus<\/strong>: Class III designation ensures professional administration standards<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-commercial-implementation\">Commercial Implementation<\/h3>\n\n\n\n<p>Huadong Medicine&#8217;s established pharmaceutical distribution network and medical aesthetics expertise position the company to rapidly deploy Ellans\u00e9 M across China&#8217;s premium medical aesthetic clinics. The product complements the company&#8217;s existing portfolio of aesthetic and dermatological products.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market positioning, and commercial expectations. Actual market adoption, competitive responses, and revenue generation may differ based on physician training requirements, patient acceptance, and evolving aesthetic treatment preferences.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u83b7\u5f97\u533b\u7597\u5668\u68b0\u6ce8\u518c\u8bc1\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u83b7\u5f97\u533b\u7597\u5668\u68b0\u6ce8\u518c\u8bc1\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-70289ae4-face-44db-abbf-8b0899148d63\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u83b7\u5f97\u533b\u7597\u5668\u68b0\u6ce8\u518c\u8bc1\u7684\u516c\u544a.pdf\">\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u83b7\u5f97\u533b\u7597\u5668\u68b0\u6ce8\u518c\u8bc1\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u83b7\u5f97\u533b\u7597\u5668\u68b0\u6ce8\u518c\u8bc1\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-70289ae4-face-44db-abbf-8b0899148d63\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received marketing approval from China&#8217;s National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[114,100,15,887],"class_list":["post-63924","post","type-post","status-publish","format-standard","hentry","category-company","category-medical-device","tag-huadong-medicine","tag-medical-aesthetics","tag-product-approvals","tag-she-000963"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huadong Medicine Secures NMPA Approval for Ellans\u00e9 M PCL Microsphere Filler for Temple Hollowing Correction - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received marketing approval from China&#039;s National Medical Products Administration (NMPA) for Ellans\u00e9 M, an injectable polycaprolactone (PCL) microsphere facial filler. The Class III medical device is specifically indicated for improving mild-to-moderate temple hollowing in adults when injected into the supraperiosteal layer, representing a significant advancement in regenerative aesthetic treatments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63924\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine Secures NMPA Approval for Ellans\u00e9 M PCL Microsphere Filler for Temple Hollowing Correction\" \/>\n<meta property=\"og:description\" content=\"Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received marketing approval from China&#039;s National Medical Products Administration (NMPA) for Ellans\u00e9 M, an injectable polycaprolactone (PCL) microsphere facial filler. The Class III medical device is specifically indicated for improving mild-to-moderate temple hollowing in adults when injected into the supraperiosteal layer, representing a significant advancement in regenerative aesthetic treatments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63924\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-24T13:21:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-24T13:21:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63924#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63924\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine Secures NMPA Approval for Ellans\u00e9 M PCL Microsphere Filler for Temple Hollowing Correction\",\"datePublished\":\"2026-04-24T13:21:44+00:00\",\"dateModified\":\"2026-04-24T13:21:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63924\"},\"wordCount\":372,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Huadong Medicine\",\"Medical aesthetics\",\"Product approvals\",\"SHE: 000963\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63924#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63924\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63924\",\"name\":\"Huadong Medicine Secures NMPA Approval for Ellans\u00e9 M PCL Microsphere Filler for Temple Hollowing Correction - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-24T13:21:44+00:00\",\"dateModified\":\"2026-04-24T13:21:45+00:00\",\"description\":\"Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received marketing approval from China's National Medical Products Administration (NMPA) for Ellans\u00e9 M, an injectable polycaprolactone (PCL) microsphere facial filler. The Class III medical device is specifically indicated for improving mild-to-moderate temple hollowing in adults when injected into the supraperiosteal layer, representing a significant advancement in regenerative aesthetic treatments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63924#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63924\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63924#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine Secures NMPA Approval for Ellans\u00e9 M PCL Microsphere Filler for Temple Hollowing Correction\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine Secures NMPA Approval for Ellans\u00e9 M PCL Microsphere Filler for Temple Hollowing Correction - Insight, China&#039;s Pharmaceutical Industry","description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received marketing approval from China's National Medical Products Administration (NMPA) for Ellans\u00e9 M, an injectable polycaprolactone (PCL) microsphere facial filler. The Class III medical device is specifically indicated for improving mild-to-moderate temple hollowing in adults when injected into the supraperiosteal layer, representing a significant advancement in regenerative aesthetic treatments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63924","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine Secures NMPA Approval for Ellans\u00e9 M PCL Microsphere Filler for Temple Hollowing Correction","og_description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received marketing approval from China's National Medical Products Administration (NMPA) for Ellans\u00e9 M, an injectable polycaprolactone (PCL) microsphere facial filler. The Class III medical device is specifically indicated for improving mild-to-moderate temple hollowing in adults when injected into the supraperiosteal layer, representing a significant advancement in regenerative aesthetic treatments.","og_url":"https:\/\/flcube.com\/?p=63924","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-24T13:21:44+00:00","article_modified_time":"2026-04-24T13:21:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63924#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63924"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine Secures NMPA Approval for Ellans\u00e9 M PCL Microsphere Filler for Temple Hollowing Correction","datePublished":"2026-04-24T13:21:44+00:00","dateModified":"2026-04-24T13:21:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63924"},"wordCount":372,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Huadong Medicine","Medical aesthetics","Product approvals","SHE: 000963"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63924#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63924","url":"https:\/\/flcube.com\/?p=63924","name":"Huadong Medicine Secures NMPA Approval for Ellans\u00e9 M PCL Microsphere Filler for Temple Hollowing Correction - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-24T13:21:44+00:00","dateModified":"2026-04-24T13:21:45+00:00","description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received marketing approval from China's National Medical Products Administration (NMPA) for Ellans\u00e9 M, an injectable polycaprolactone (PCL) microsphere facial filler. The Class III medical device is specifically indicated for improving mild-to-moderate temple hollowing in adults when injected into the supraperiosteal layer, representing a significant advancement in regenerative aesthetic treatments.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63924#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63924"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63924#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine Secures NMPA Approval for Ellans\u00e9 M PCL Microsphere Filler for Temple Hollowing Correction"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63924"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63924\/revisions"}],"predecessor-version":[{"id":63926,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63924\/revisions\/63926"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}